They decided that NutropinAq’ s benefits are greater than its risks for the treatment of growth hormone deficiency in adults and children.
Komitee otsustas, et NutropinAqi kasulikkus kasvuhormooni puudulikkuse ravis täiskasvanutel ja lastel on suurem kui sellega kaasnevad riskid.